Savara Inc (NASDAQ: SVRA) recently announced that it has received a Day 74 letter from the U.S. Food and Drug Administration (FDA).

The letter clearly states that the FDA currently has no plans to convene an advisory committee meeting. This development marks an important step forward for Savara in the regulatory approval process. Typically, the FDA conducts in-depth evaluations of innovative therapies through advisory committee meetings, and the decision not to hold such a meeting this time may indicate an accelerated approval process. The company stated that it will continue to maintain close communication with the FDA and actively advance the review of the relevant drug. The market is watching to see whether this move means Savara's R&D project will receive faster regulatory feedback.